[1] |
Amedeo L,Fabio N,Mauro M,et al.Nonalcoholic fatty liver disease:Evolving paradigms[J].World J Gastroenterol,2017,23(36):6571-6592.
|
[2] |
Fan JG,Kim SU,Wong VW.New trends on obesity and NAFLD in Asia[J].J Hepatol,2017,67(4):862-873.
|
[3] |
Chao Y,Yang SJ,Xu WW,et al.Association between thehyperuricemia and nonalcoholic fatty liver disease risk in a Chinesepopulation:a retrospective cohort study[J].PLoS One,2017,12(5):e0177249.
|
[4] |
中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].现代医药卫生,2018,34(5):641-649.
|
[5] |
Ivana M,Sandra M,Tamara TW,et al.Nonalcoholic fatty liver disease——a multisystem disease?[J].World J Gas troenterol,2016,22(43):9488-9505.
|
[6] |
Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepa tology,2016,64(1):73-84.
|
[7] |
Zhu JZ,Zhou QY,Wang YE,et al.Prevalence of fatty liver disease and the economy in China:a systematic review[J].World J Gastroenterol,2015,21(18):5695-5706.
|
[16] |
白俊玺,舒仁明,黄勇,等.血尿酸与非酒精性脂肪性肝病发生风险相关性随访队列研究[J].中华肝脏病杂志,2018,26(4):271-275.
|
[17] |
Romero G,Zelber S,Treneli M.Treatment of NAFLD with diet,physical activity and exercise[J].J Hepatol,2017,67(4):829-846.
|
[8] |
Kwok R,Choi KC,Wong GL,et al.Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:aprospective cohort study[J].Gut,2016,65(8):1359-1368.
|
[9] |
Zhang RN,Zhang RD,Mi YQ,et al.APOC3 rs2070666 is associated with the severity of hepatic steatosis independently of PNPLA3 rs738409 in Chinese patients with nonalcoholic fatty liverdiseases[J].Dig Dis Sci,2016,61(8):2284-2293.
|
[10] |
Bedossa P,Flip Pathology Consortium.Utility and appropriateness of the fatty liver inhibition of progression(FLIP)algorithm and steatosis,activity,and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease[J].Hepatology,2014,60(2):565-575.
|
[11] |
Chitturi S,Wong VW,Chan WK,et al.The Asia Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 2:management and special groups[J].J Gastroenterol Hepatol,2018,33(1):86-98.
|
[12] |
Xu L,Lu W,Li P,et al.A comparison of hepatic steatosis index,controlled attenuation parameter,and ultrasound as noninvasive diagnostic tools for hepatic steatosis in patients with biopsy-proven chronic hepatitis B[J].Dig Liver Dis,2017,49(8):910-917.
|
[13] |
Zhang HJ,Pan LL,Ma ZM,et al.Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults:a 1-year follow up study[J].Diabetes Obes Metab,2017,19(2):284-289.
|
[14] |
Zheng XY,Gong LL,Luo R,et al.Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults[J].Lipids Health Dis,2017,16(10):202.
|
[15] |
Rosa L,Giuseppina P,Silvia F.Role of serum uric acid and ferritin in the development and progression of NAFLD[J].Int J Mol Sci,2016,17(4):548.
|